美托洛尔联合曲美他嗪治疗冠心病心力衰竭的应用价值分析

Analysis of application value of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure

目的探索美托洛尔联合曲美他嗪治疗冠心病心力衰竭的应用价值。方法 90例冠心病心力衰竭患者,随机分为对照组和观察组,每组45例。对照组患者采用常规治疗,观察组患者采用美托洛尔联合曲美他嗪治疗。观察比较两组患者治疗前后的心功能指标[左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左室射血分数(LVEF)、6 min步行距离]、C反应蛋白(CRP)、脑利钠肽(BNP)及不良反应发生情况。结果治疗前,两组患者的LVEDD、LVESD、LVEF、6 min步行距离比较差异无统计学意义(P>0.05);治疗后,观察组患者的LVEDD、LVESD、LVEF、6 min步行距离水平均优于对照组,差异具有统计学意义(P<0.05)。治疗前,两组患者的CRP、BNP水平比较差异无统计学意义(P>0.05);治疗后,观察组患者的CRP(2.21±1.36)mg/L、BNP(105.65±30.27)ng/L均低于对照组的(5.42±1.75)mg/L、(288.54±25.54)ng/L,差异具有统计学意义(P<0.05)。观察组和对照组患者的不良反应发生率分别为6.67%和11.11%,两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论美托洛尔联合曲美他嗪治疗冠心病心力衰竭效果显著。

Objective To investigate the application value of metoprolol combined with trimetazidine in the treatment of coronary heart disease and heart failure. Methods A total of 90 patients with coronary heart disease and heart failure were randomly divided into control group and observation group, with 45 cases in each group. The control group was treated with conventional therapy, and the observation group was treated with metoprolol combined with trimetazidine. Observation and comparison were made on cardiac function indicators[left ventricular end-diastolic diameter(LVEDD), left ventricular end-systolic diameter(LVESD), left ventricular ejection fraction(LVEF), 6 minute walking distance] before and after treatment, C-reactive protein(CRP), brain natriuretic peptide(BNP) and adverse reactions between the two groups. Results Before treatment, both groups had no statistically significant difference in LVEDD, LVESD, LVEF and 6 min walking distance(P>0.05). After treatment, the observation group had better LVEDD, LVESD, LVEF and 6 min walking distance than the control group, and the difference was statistically significant(P<0.05). Before treatment, both groups had no statistically significant difference in CRP and BNP level(P>0.05). After treatment, the observation group had lower CRP as(2.21±1.36) mg/L, BNP as(105.65±30.27) ng/L than(5.42±1.75) mg/L and(288.54±25.54) ng/L in the control group, and their difference was statistically significant(P<0.05). The observation group and control group had incidence of adverse reactions respectively as 6.67% and 11.11%, and both groups had no statistically significant difference in incidence of adverse reactions(P>0.05). Conclusion Metoprolol combined with trimetazidine has a significant effect in the treatment of coronary heart disease and heart failure.